Suppr超能文献

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

作者信息

Tandstad Torgrim, Kollmannsberger Christian K, Roth Bruce J, Jeldres Claudio, Gillessen Silke, Fizazi Karim, Daneshmand Siamak, Lowrance William T, Hanna Nasser H, Albany Costantine, Foster Richard, Cedermark Gabriella Cohn, Feldman Darren R, Powles Thomas, Lewis Mark A, Grimison Peter Scott, Bank Douglas, Porter Christopher, Albers Peter, De Santis Maria, Srinivas Sandy, Bosl George J, Nichols Craig R

机构信息

Torgrim Tandstad, St Olavs University Hospital, Trondheim, Norway; Christian K. Kollmannsberger, University of British Columbia, Vancouver, British Columbia, Canada; Bruce J. Roth, Washington University School of Medicine, St Louis, MO; Claudio Jeldres, Sherbrooke University, Sherbrooke, Quebec, Canada; Silke Gillessen, Kantonsspital, St Gallen, Switzerland; Karim Fizazi, University of Paris Sud, Paris, France; Siamak Daneshmand, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA; William T. Lowrance, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Nasser H. Hanna, Indiana University School of Medicine, Indianapolis, IN; Gabriella Cohn Cedermark, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Darren R. Feldman, Memorial Sloan Kettering Cancer Center and Weill Medical Cornell Medical College, New York, NY; Thomas Powles, Barts Cancer Institute, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; Mark A. Lewis, Intermountain Health, Salt Lake City, UT; Peter Scott Grimison, University of Sydney, Sydney, New South Wales, Australia; Douglas Bank, Testicular Cancer Resource Center, Riverwoods, IL; Christopher Porter, Virginia Mason Medical Center, Seattle, WA; Peter Albers, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; Maria De Santis, Cancer Research Center, University of Warwick, Coventry, United Kingdom; Sandy Srinivas, Stanford University School of Medicine, Stanford, CA; George J. Bosl, Memorial Sloan Kettering Cancer Center, New York, NY; and Craig R. Nichols, Precision Genomics Cancer Research Clinic, Intermountain Health, Salt Lake City, UT; Testicular Cancer Commons, Portland, OR.

出版信息

J Clin Oncol. 2017 Nov 1;35(31):3525-3528. doi: 10.1200/JCO.2017.73.4723. Epub 2017 Aug 30.

DOI:10.1200/JCO.2017.73.4723
PMID:28854068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5791831/
Abstract
摘要

相似文献

1
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.
J Clin Oncol. 2017 Nov 1;35(31):3525-3528. doi: 10.1200/JCO.2017.73.4723. Epub 2017 Aug 30.
2
[Diagnosis and therapy of testicular tumors].
Urologe A. 2002 Jul;41(4):374-85; quiz 386-7. doi: 10.1007/s00120-002-0219-x.
3
Treatment options for patients with stage I nonseminomatous testis cancer: it's all good.
Eur Urol. 2011 Apr;59(4):563-5. doi: 10.1016/j.eururo.2011.01.012. Epub 2011 Jan 18.
4
[Therapy of germ cell tumors. Model for interdisciplinary treatment approach].
Med Klin (Munich). 1996 Apr 12;91 Suppl 3:80-4.
5
A third option in the management of patients with clinical stage I nonseminomatous germ cell tumor?
J Clin Oncol. 1990 Jan;8(1):4-8. doi: 10.1200/JCO.1990.8.1.4.
6
[Germ cell tumors of the testis].
Wien Klin Wochenschr. 1994;106(2):37-44.
7
[Testicular tumors--a curable disease?].
Schweiz Rundsch Med Prax. 1988 May 17;77(20):560-4.
8
Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.
Andrology. 2015 Jan;3(1):102-10. doi: 10.1111/andr.280. Epub 2014 Oct 1.
9
[Once fatal, now curable!].
Laeknabladid. 2011 Mar;97(3):141. doi: 10.17992/lbl.2011.03.353.
10
Editorial Comment to Clinical characteristics and survival outcomes of elderly patients with de novo metastatic germ cell tumors.
Int J Urol. 2024 Jul;31(7):812. doi: 10.1111/iju.15525. Epub 2024 Jun 28.

引用本文的文献

1
Global trends in testicular and prostate cancer among adolescents and young adult males aged 15-49 years, 1990-2021: insights from the GBD study.
Sci Rep. 2025 Jul 2;15(1):23388. doi: 10.1038/s41598-025-07361-3.
2
High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed or refractory testicular cancer: a systematic review and meta-analysis.
Front Oncol. 2024 Oct 1;14:1437574. doi: 10.3389/fonc.2024.1437574. eCollection 2024.
3
SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).
Clin Transl Oncol. 2024 Nov;26(11):2783-2799. doi: 10.1007/s12094-024-03532-2. Epub 2024 Jul 3.
4
Trends in the global, regional, and national burden of testicular cancer from 1990 to 2019: an observational study with 30-year global data.
Int J Surg. 2024 Aug 1;110(8):4633-4647. doi: 10.1097/JS9.0000000000001603.
5
Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment.
Nat Commun. 2023 Dec 20;14(1):8462. doi: 10.1038/s41467-023-44305-9.
6
Radiomics and Clinicopathological Characteristics for Predicting Lymph Node Metastasis in Testicular Cancer.
Cancers (Basel). 2023 Nov 29;15(23):5630. doi: 10.3390/cancers15235630.
7
Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours.
Int J Mol Sci. 2023 Jan 27;24(3):2495. doi: 10.3390/ijms24032495.
8
Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center.
Medicina (Kaunas). 2023 Jan 10;59(1):133. doi: 10.3390/medicina59010133.
9
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.
Ther Adv Med Oncol. 2022 Mar 31;14:17588359221086813. doi: 10.1177/17588359221086813. eCollection 2022.
10
Narrative review of developing new biomarkers for decision making in advanced testis cancer.
Transl Androl Urol. 2021 Oct;10(10):4075-4084. doi: 10.21037/tau-20-1246.

本文引用的文献

1
Patterns of performance of retroperitoneal lymph node dissections by American urologists: most retroperitoneal lymph node dissections in the United States are performed by low-volume surgeons.
Urology. 2014 Dec;84(6):1325-8. doi: 10.1016/j.urology.2014.07.054. Epub 2014 Oct 11.
2
Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.
Andrology. 2015 Jan;3(1):102-10. doi: 10.1111/andr.280. Epub 2014 Oct 1.
3
Monitoring the delivery of cancer care: Commission on Cancer and National Cancer Data Base.
Surg Oncol Clin N Am. 2012 Jul;21(3):377-88, vii. doi: 10.1016/j.soc.2012.03.005. Epub 2012 Apr 17.
4
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Epub 2008 May 5.
5
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.
J Natl Cancer Inst. 1999 May 19;91(10):839-46. doi: 10.1093/jnci/91.10.839.
6
Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer.
J Natl Cancer Inst. 1999 May 19;91(10):816-8. doi: 10.1093/jnci/91.10.816.
7
Management of malignant teratoma: does referral to a specialist unit matter?
Lancet. 1993 Apr 17;341(8851):999-1002. doi: 10.1016/0140-6736(93)91082-w.
8
After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.
J Clin Oncol. 1994 Feb;12(2):368-77. doi: 10.1200/JCO.1994.12.2.368.
9
Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture.
Cancer Res. 1981 Sep;41(9 Pt 1):3275-80.
10
Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
J Clin Oncol. 1991 May;9(5):818-26. doi: 10.1200/JCO.1991.9.5.818.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验